The September 2017 amendments to the Patented Medicines (Notice of Compliance) Regulations introduced a new scheme for pharmaceutical patent linkage litigation in Canada. That scheme is now much closer to the United States' (US) Hatch-Waxman scheme, but with remaining key differences that are explained in this chart.
Canada is an attractive market for pharmaceutical manufacturers. Most Canadian consumers have some form of drug coverage through government programs and/or private insurance. Below are ten patent and regulatory topics that in-house counsel need to know before bringing an innovative product to Canada.
Editor's note: This article was updated to reflect recent developments; the original version of this article was published on December 16, 2020.
In this Sample Trade Secret Policy, in-house counsel can review informative language about trade secrets and how to define them for potential new employees in the United States.
In this Sample Acknowledgement Form, an incoming employee is reviewing and acknowledging the trade secrets policy the hiring company has instituted.
In this example of possible "Notice" language about Whistleblower Immunity, language is constructed to inform a possible whistleblower of their rights and immunity.
In this Sample Exit Interview Form, a United States Company is categorizing access to tools and information from the former employee.
This ACC Guide provides an overview on trade secrets in the United States. It will explain the legal framework that in-house counsel can use to inform, protect, and provide guidance when dealing with trade secrets, intellectual property usage, and what you company might face in attempting to protect certain information.